Carboplatin (Investigator discretion)

DRUG2 trials

Sponsors

G1 Therapeutics, Inc., Shanghai Henlius Biotech

Conditions

Breast CancerNSCLC (Advanced Non-small Cell Lung Cancer)Triple Negative Breast Cancer

Phase 2

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

CompletedNCT05112536

G1 Therapeutics, Inc.Triple Negative Breast Cancer, Breast Cancer

Start: 2022-03-03End: 2023-03-13Updated: 2024-03-12

A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruitingNCT07865910

Shanghai Henlius BiotechNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2026-11-30End: 2031-12-30Target: 1438Updated: 2026-10-08

Related Papers

Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.

2023-07-073 citations

Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.

Journal of Clinical Oncology2023-06-011 citations

Abstract 6674: Single-dose trilaciclib monotherapy potentiates antitumor immunity in the neoadjuvant setting of triple-negative breast cancer by modulating the composition and effector function of peripheral immune cells

Cancer Research2023-04-04

Abstract P3-06-03: Trilaciclib induces immune changes within the tumor microenvironment in early-stage triple-negative breast cancer

Cancer Research2023-03-01